MEIRAGTX HOLDINGS PLC (MGTX) Stock Price, Forecast & Analysis
USA - NASDAQ:MGTX - KYG596651029 - Common Stock
MGTX Key Statistics, Chart & Performance
The current stock price of MGTX is 7.44 USD. In the past month the price decreased by -15.09%. In the past year, price increased by 25.3%.
MGTX Latest News, Press Relases and Analysis
MGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25.11 | 419.11B | ||
| AMGN | AMGEN INC | 15.6 | 183.63B | ||
| GILD | GILEAD SCIENCES INC | 15.61 | 158.66B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.97 | 111.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.1 | 56.96B | ||
| INSM | INSMED INC | N/A | 42.14B | ||
| NTRA | NATERA INC | N/A | 31.93B | ||
| BIIB | BIOGEN INC | 10.07 | 24.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.98 | 21.46B | ||
| INCY | INCYTE CORP | 15.93 | 19.97B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About MGTX
Company Profile
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 386 full-time employees. The company went IPO on 2018-06-08. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Company Info
MEIRAGTX HOLDINGS PLC
655 Third Avenue, Suite 1115
New York City NEW YORK 10016 US
CEO: Alexandria Forbes
Employees: 386
Phone: 16468607985
MEIRAGTX HOLDINGS PLC / MGTX FAQ
Can you describe the business of MEIRAGTX HOLDINGS PLC?
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 386 full-time employees. The company went IPO on 2018-06-08. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Can you provide the latest stock price for MEIRAGTX HOLDINGS PLC?
The current stock price of MGTX is 7.44 USD. The price increased by 0.13% in the last trading session.
What is the dividend status of MEIRAGTX HOLDINGS PLC?
MGTX does not pay a dividend.
What is the ChartMill rating of MEIRAGTX HOLDINGS PLC stock?
MGTX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does MEIRAGTX HOLDINGS PLC belong to?
MEIRAGTX HOLDINGS PLC (MGTX) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of MEIRAGTX HOLDINGS PLC (MGTX)?
MEIRAGTX HOLDINGS PLC (MGTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.04).
What is the outstanding short interest for MEIRAGTX HOLDINGS PLC?
The outstanding short interest for MEIRAGTX HOLDINGS PLC (MGTX) is 7.38% of its float.
MGTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MGTX. When comparing the yearly performance of all stocks, MGTX is one of the better performing stocks in the market, outperforming 80.51% of all stocks.
MGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MGTX. MGTX may be in some trouble as it scores bad on both profitability and health.
MGTX Financial Highlights
Over the last trailing twelve months MGTX reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 8.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.26% | ||
| ROE | -5321.11% | ||
| Debt/Equity | 24.92 |
MGTX Forecast & Estimates
13 analysts have analysed MGTX and the average price target is 28.12 USD. This implies a price increase of 277.99% is expected in the next year compared to the current price of 7.44.
For the next year, analysts expect an EPS growth of 13.44% and a revenue growth 413.04% for MGTX